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Summary
 
Severe congenital neutropenia (SCN) is a heterogeneous condition characterized by a drastic
reduction in circulating neutrophils and a maturation arrest of myeloid progenitor cells in the
bone marrow. Usually this condition can be successfully treated with granulocyte colony-stim-
ulating factor (G-CSF). Here we describe the identification of a novel point mutation in the
extracellular domain of the G-CSF receptor (G-CSF-R) in an SCN patient who failed to re-
spond to G-CSF treatment. When this mutant G-CSF-R was expressed in myeloid cells, it was
defective in both proliferation and survival signaling. This correlated with diminished activa-
tion of the receptor complex as determined by signal transducer and activator of transcription
(STAT) activation, although activation of STAT5 was more affected than STAT3. Interest-
ingly, the mutant receptor showed normal affinity for ligand, but a reduced number of ligand
binding sites compared with the wild-type receptor. This suggests that the mutation in the ex-
tracellular domain affects ligand–receptor complex formation with severe consequences for in-
tracellular signal transduction. Together these data add to our understanding of the mechanisms
of cytokine receptor signaling, emphasize the role of 
 
GCSFR
 
 mutations in the etiology of
SCN, and implicate such mutations in G-CSF hyporesponsiveness.
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S
 
evere congenital neutropenia (SCN)
 
1
 
 is a heterogeneous
disease state characterized by a severe reduction in cir-
culating neutrophils (
 
,
 
0.2 
 
3 
 
10
 
9
 
/liter), and a maturation
arrest of bone marrow progenitor cells at the promyelo-
cyte/myeloid stage (1–3). Myeloid progenitor cells from
SCN patients frequently show reduced responsiveness to
G-CSF in vitro (4, 5). Moreover, treatment with pharma-
cological doses of G-CSF is able to restore the neutrophil
count in the majority of SCN patients (5–7).
G-CSF is known to play a crucial role in the regulation
of granulopoiesis by stimulating the proliferation, survival,
and maturation of myeloid progenitor cells (8–11). The
various biological effects of G-CSF are mediated through
the G-CSF receptor (G-CSF-R), a member of the he-
matopoietin receptor superfamily which forms homo-
oligomeric complexes upon ligand binding (12, 13). The
G-CSF-R, like other hematopoietin receptors, lacks intrin-
sic tyrosine kinase activity but activates cytoplasmic ty-
rosine kinases (9, 12). Signal transduction pathways that in-
volve Janus tyrosine kinases (Jak1, Jak2, and Tyk2) and
signal transducer and activator of transcription proteins
(STATs 1, 3, and 5) have been linked to the G-CSF-R
(14–22). Activation of STAT3 has been implicated in
G-CSF–mediated differentiation (23), whereas STAT5 ap-
pears to have an important function in G-CSF–mediated
proliferation and survival (24).
We have previously identified in a subset of SCN patients
nonsense mutations in the gene encoding the G-CSF-R
that truncate the COOH-terminal domain of the receptor
 
1
 
Abbreviations used in this paper:
 
 CRH, cytokine receptor homologous;
RT, reverse transcription; SCN, severe congenital neutropenia; STAT,
signal transducer and activator of transcription.
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(25–27). When expressed in myeloid cells, these truncated
receptors transduce a strong growth signal but are defective
in maturation signaling (26, 28). This is due to sustained re-
ceptor activation caused by defective internalization and an
altered balance of STAT activation (22, 29, 30). However,
in SCN patients with this mutation, G-CSF treatment is
able to reverse the neutropenia (25–27).
Here we describe the analysis of an SCN patient unre-
sponsive to standard G-CSF treatment. We identify a novel
point mutation in the extracellular domain of the G-CSF-R
in this patient. This mutation changes a highly conserved
proline to histidine at position 206 of the cytokine receptor
homologous (CRH) domain, which is part of a proline-
rich “hinge” motif located between the NH
 
2
 
- and
COOH-terminal “barrels” of the CRH domain. When
this mutant receptor was expressed in myeloid 32D cells, it
was defective in both G-CSF–mediated proliferation and
survival. This correlated with greatly diminished activation
of the receptor complex, and severe but selective abroga-
tion of signaling from the mutant G-CSF-R. The mutant
receptor showed a normal affinity of ligand binding, but a
reduction in the number of ligand binding sites per recep-
tor. This suggests that the mutation in the extracellular do-
main alters the architecture of the ligand–receptor com-
plex, which severely affects intracellular signaling and
cellular responses to G-CSF. These data contribute to our
understanding of cytokine receptor signaling, and further
emphasize the role of 
 
GCSFR
 
 mutations in the etiology of
both SCN and hyporesponsiveness to G-CSF therapy.
 
Materials and Methods
 
Patient Details.
 
The patient is female, born November 1990,
the only child of healthy, unrelated parents. At birth, the patient’s
absolute neutrophil count was 0 
 
3
 
 10
 
9
 
/liter. During the first 18 mo
of life, the patient experienced four episodes of cellulitis and ab-
scesses. From June 1992 to October 1993, the patient was treated
with a series of escalating daily subcutaneous doses of G-CSF
from 10 to 70 
 
m
 
g/kg, with no response; peripheral polymorpho-
nuclear cells remained at 0 
 
3
 
 10
 
9
 
/liter, and bone marrow smears
revealed a maturation arrest at the myelocyte stage, indicative of
severe congenital neutropenia. In January 1994, a continuous in-
travenous 24-h infusion of 150–200 
 
m
 
g/kg G-CSF was adminis-
tered to the patient for 10 d consecutively with no response and
persistent marrow maturation arrest. The patient continued to
have recurrent bacterial infections.
 
Reverse Transcription PCR and Nucleotide Sequence Analysis.
 
Total RNA was isolated from bone marrow mononuclear cells
using acid guanidinium isothiocyanate extraction (31), and re-
verse-transcribed using oligo(dT) primers and MMLV reverse
transcriptase (GIBCO BRL). PCR amplification was performed
using the primer pairs GRFR3 (5
 
9
 
-TCGGAAAGGTGAAG-
TAACTTGTCC) and GRRV5 (5
 
9
 
-TCCATGGGATCAAGA-
CACAG) to amplify nucleotides 106–832, and GRFR5 (5
 
9
 
-TG-
CAGGCAGAGAATGCGCTG) and GRRV4 (5
 
9
 
-AGGGTC-
CCATGGTGTCCTGGTACA) to amplify nucleotides 772–1707
of the 
 
GCSFR
 
 cDNA. The products were cloned into the TA
cloning vector (Invitrogen) and sequenced using the dideoxy
chain termination method with T7 polymerase (Amersham Phar-
macia Biotech).
 
Analysis of Genomic DNA.
 
The 
 
GCSFR
 
 mutation identified
in patient AR introduces a new BsiHkAI site (G
 
A
 
/
 
t
 
GC
 
A
 
/
 
t
 
C)
(see Fig. 1 B). Therefore, to analyze for the presence of the muta-
tion, genomic DNA was prepared from fibroblast and blood cells
using standard techniques, and subjected to PCR with the primer
pair GRFRI6 (5
 
9
 
-ACCTAGAGAGAAACAAAGAC) and
GRRV15 (5
 
9
 
-AGCGGATGCAGCGTATCT). The resultant
products were digested with BsiHkAI (New England Biolabs)
before separation on a 3% agarose gel.
 
Cell Culture.
 
The subline of the IL-3–dependent murine
myeloid cell line 32Dcl3, called 32D.cl8.6 (29), and the IL-3–
dependent murine pro-B cell line Ba/F3 (32) were maintained
in RPMI 1640 medium supplemented with 10% FCS and 10
ng/ml of murine IL-3, at 37
 
8
 
C and 5% CO
 
2
 
.
 
Plasmid Construction, Transfections, and Infections.
 
Cloning of
the wild-type (WT) 
 
GCSFR
 
 cDNA into the eukaryotic expres-
sion vector pLNCX (33) has been described previously (25). To
clone the mutant receptor (mAR) into this vector, a multistep
procedure was required. First, the region spanning the extracellu-
lar region of the mutant receptor was obtained by joining the 5
 
9
 
and 3
 
9
 
 regions obtained using reverse transcription (RT)-PCR
via a common BsmI site at position 782, to produce plasmid
pTAR1600. From this construct, the region encoding the muta-
tion was obtained as an AvaI fragment which was used to replace
the equivalent region of the WT 
 
GCSFR
 
 cloned into pBlue-
Script. The entire receptor coding region was then subcloned
into pLNCX as a HindIII-ClaI fragment. The pLNCX expres-
sion constructs were linearized by PvuI digestion and transfected
into 32D.cl8.6 or Ba/F3 cells by electroporation. After 48 or 24 h
of incubation, respectively, cells were selected with G418
(GIBCO BRL) at a concentration of 0.8 or 1.2 mg/ml, respec-
tively, with multiple clones expanded for further analysis. For ret-
roviral infections, the WT and mAR 
 
GCSFR
 
 cDNAs were
cloned into pBabe, as described (25). The resulting plasmids were
transfected into the Phoenix A amphotropic packaging cell line
(Clontech) to generate recombinant retrovirus, following stan-
dard protocols. Virus supernatants were used to infect 32D cells
harboring the pLNCX.GCSFR(WT) vector (32D[WT
 
Neo
 
]) us-
ing RetroNectin™ (Takara Biomedicals), as described by the
manufacturer. After 48 h, puromycin was added to 1 
 
m
 
g/ml to
select for stably transduced cells.
 
Analysis of G-CSF-R Expression.
 
To determine G-CSF-R
expression levels, cells were incubated at 4
 
8
 
C for 60 min sequentially
with 10 
 
m
 
g/ml of biotinylated mouse anti–human G-CSF-R mAb
LMM741 (PharMingen), 5 
 
m
 
g/ml of PE-conjugated streptavidin,
5 
 
m
 
g/ml of biotinylated antistreptavidin antibody, and finally 2
 
m
 
g/ml of PE-conjugated streptavidin, with washing between each
antibody step. Samples were analyzed by flow cytometry using a
FACScan™ (Becton Dickinson). Several independently derived
cell lines of each construct were selected on the basis of homoge-
neous receptor expression. The 
 
GCSFR
 
 mutation identified in
patient AR introduced a new BsiHkAI site (G
 
A
 
/
 
t
 
GC
 
A
 
/
 
t
 
C).
Therefore, as confirmation of mutant receptor expression, RT-
PCR was performed with primers GRFR5 and GRRV11 (5
 
9
 
-
ACTGTCCTGGGGTCCAGCTG), and the resultant products
were cut with BsiHkAI before electrophoresis on an agarose gel.
 
Analysis of G-CSF Binding.
 
For routine analysis of G-CSF
binding, biotinylated G-CSF protein was used, followed by 5
 
m
 
g/ml of PE-conjugated streptavidin, as described (28). To esti-
mate the affinities of the G-CSF binding sites, G-CSF binding
experiments and Scatchard analysis were performed using 
 
125
 
I–
G-CSF (800–1,500 Ci/mmol; Amersham Pharmacia Biotech), as
described (34).
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DNA Synthesis Assay.
 
DNA synthesis was assessed by [
 
3
 
H]-
thymidine (
 
3
 
H-TdR) incorporation. Cells (5 
 
3 
 
10
 
4
 
) were incu-
bated in triplicate in 100 
 
m
 
l of 10% FCS/RPMI medium supple-
mented with titrated concentrations of human G-CSF, or with
10 ng/ml murine IL-3, in 96-well plates for 24 h. 16 h before cell
harvest, 0.1 
 
m
 
Ci of 
 
3
 
H-TdR (2 Ci/mmol; Amersham Pharmacia
Biotech) was added to each well. 
 
3
 
H-TdR incorporation was
measured by harvesting cells on glass fiber filters followed by
counting on a Packard Top Count scintillation counter.
 
Cell Proliferation and Morphological Analysis.
 
To determine pro-
liferation, cells were incubated at an initial density of 1–2 
 
3 
 
10
 
5
 
cells/ml in 10% FCS/RPMI medium supplemented with 100
ng/ml of human G-CSF, 10 ng/ml of murine IL-3, or without
growth factors. The medium was replenished every 1–2 d, and
the cell densities were adjusted to 1–2 
 
3 
 
10
 
5
 
 cells/ml. Viable cells
were counted on the basis of trypan blue exclusion. To analyze
the morphological features, cells were spun onto glass slides and
examined after May-Grünwald-Giemsa staining.
 
Preparation of Nuclear Extracts.
 
Cells were deprived of serum
and factors for 4 h at 37
 
8
 
C in RPMI 1640 medium at a density of
10
 
6
 
/ml, and then stimulated with either RPMI 1640 medium
alone or in the presence of 100 ng/ml human G-CSF. At differ-
ent time points, 10 vol of ice-cold PBS supplemented with 10 
 
m
 
M
Na
 
3
 
VO
 
4
 
 were added. Subsequently, cells were pelleted and resus-
pended in ice-cold hypotonic buffer (20 mM Hepes, pH 7.8,
20 mM NaF, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM Na
 
4
 
P
 
2
 
O
 
7
 
, 1 mM dithiothre-
itol, 1 mM EDTA, 1 mM EGTA, 0.2% Tween-20, 0.125 
 
m
 
M
okadaic acid, 1 mM Pefabloc SC, 50 
 
m
 
g/ml aprotinin, 50 
 
m
 
g/ml
leupeptin, 50 
 
m
 
g/ml bacitracin, and 50 
 
m
 
g/ml iodoacetamide)
(35). Cells were vortexed for 10 s, and the nuclei were pelleted
by centrifugation at 15,000 
 
g
 
 for 30 s. Nuclear extracts were pre-
pared by resuspension of the nuclei in high-salt buffer (hypotonic
buffer with 420 mM NaCl and 20% glycerol) and extraction of
proteins by rocking for 30 min at 4
 
8
 
C. Insoluble materials were
removed by centrifugation at 4
 
8
 
C for 15 min at 15,000 
 
g
 
.
 
Electrophoretic Mobility Shift Assay.
 
Nuclear extracts of 
 
z
 
0.5 
 
3
 
10
 
6
 
 cells were incubated for 20 min at room temperature with
0.2 ng of 
 
32
 
P-labeled double-stranded oligonucleotide (5–10 
 
3
 
10
 
3
 
 cpm) and 2 
 
m
 
g of poly(dI-dC) in 20 
 
m
 
l of binding buffer
(13 mM Hepes, pH 7.8, 80 mM NaCl, 3 mM NaF, 3 mM
NaMoO
 
4
 
, 1 mM dithiothreitol, 0.15 mM EDTA, 0.15 mM
EGTA, and 8% glycerol) (36). The oligonucleotide probes used
in this study were m67 (5
 
9
 
-CATTTCCCGTAAATC), a high-
affinity mutant of the sis-inducible element (SIE) of the human
c-
 
fos
 
 gene (37), which binds STAT1 and STAT3, and 
 
b
 
-cas (5
 
9
 
-
AGATTTCTAGGAATTCAATCC), derived from the 5
 
9
 
 re-
gion of the 
 
b
 
-casein gene (38), which binds STAT5 and STAT1.
The DNA–protein complexes were separated by electrophoresis
on 5% polyacrylamide gels containing 5% glycerol in 0.253
TBE. The gels were dried and subsequently analyzed by autora-
diography.
Results
Identification of a Mutation in the G-CSF-R Extracellular Do-
main in an SCN Patient Hyporesponsive to G-CSF Therapy.
Patient AR represents an unusual SCN patient, being to-
tally unresponsive to standard and high-dose G-CSF ther-
apy. Subsequently, the patient responded to combined
prednisone therapy in combination with G-CSF, the de-
tails of which will be published elsewhere (Ward, A.C.,
I.P. Touw, and M.H. Freedman, manuscript in prepara-
tion). We had previously reported that no mutations were
present in the sequence encoding the cytoplasmic domain
of the G-CSF-R of this patient (27). However, the unusual
phenotype of this patient prompted us to analyze the com-
plete sequence of the GCSFR. This identified a Cfi A mu-
tation at nucleotide 850 of the GCSFR cDNA, which pro-
Figure 1. Identification of a point mutation in the GCSFR cDNA of an SCN patient hyporesponsive to G-CSF. (A) Partial nucleotide sequence of
the mutant and wild-type GCSFR cDNA, with the relative position of the corresponding P206H mutation in the encoded G-CSF-R indicated. (B)
Analysis of fibroblast chromosomal DNA for the presence of the mutation. The relevant genomic region of the GCSFR gene is presented (top), along
with the relative positions of the primers used for PCR (GRFWI6 and GRRV15). The BsiHkAI restriction sites are also indicated, with the new site in-
troduced by the mAR mutation shown in parentheses. Digestion of a wild-type allele predictively generates two fragments, a and b, whereas digestion of
a mutant allele generates three fragments, a9, a99, and b, as indicated. At the bottom are the results of BsiHkAI digestion of PCR products generated from
either the patient (AR) or a normal individual (WT).
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duces a Profi His substitution at position 206 (P206H) of
the mature receptor (Fig. 1 A). This change lies in the join-
ing peptide “hinge” between the NH2- and COOH-ter-
minal “barrels” (BN and BC domains) of the CRH region
of the G-CSF-R extracellular domain (39). Along with the
WSXWS sequence, this short Pro-rich stretch is highly
conserved among cytokine receptors, with the position
equivalent to 206 usually a Pro, or otherwise an Ala residue
(12, 40). This mutation was found in z50% of clones se-
quenced, indicating that essentially all bone marrow cells
possessed one mutant GCSFR allele. This was confirmed
by restriction digestion of cDNA produced in an indepen-
dent RT-PCR with the enzyme BsiHkAI, as described in
Materials and Methods. In addition, a fragment covering
the mutation site was amplified from genomic DNA iso-
lated from fibroblast cells of the patient. Restriction en-
zyme analysis with BsiHkAI revealed that both mutant and
wild-type GCSFR alleles were also present in these cells
(Fig. 1 B). Thus, unlike other GCSFR mutations reported
(25), the mutation in patient AR is not restricted to cells of
the hematopoietic system, with the patient apparently het-
erozygous for the mutation. Unfortunately, a full pedigree
for the patient was not available to determine if the muta-
tion was inherited, although the mother was found to pos-
sess a wild-type GCSFR allele and normal blood neutro-
phil counts (data not shown).
Myeloid 32D Cells Expressing the P206H Mutant G-CSF-R
Are Hyporesponsive to G-CSF. To study the functionality
of the P206H mutant G-CSF-R, designated mAR, we re-
placed the extracellular region of the wild-type G-CSF-R
with that of the mutant form. Expression vectors contain-
ing the WT and mAR GCSFR cDNAs were introduced
into the IL-3–dependent murine myeloid cell line
32D.cl8.6, which does not express endogenous G-CSF-R.
Expression levels of the different G-CSF-R proteins in the
transfectants were determined by flow cytometry using
anti–G-CSF-R antiserum (Fig. 2 A). Several independent
clones were obtained expressing approximately equivalent
levels of wild-type and P206H mutant receptors (32D[WT]
and 32D[mAR], respectively), and used in subsequent
analyses. To directly test whether the P206H mutation
could contribute to the G-CSF hyporesponsiveness ob-
served in the patient, we analyzed the sensitivity of the WT
and mAR clones to G-CSF by measuring DNA synthesis
in 3H-TdR incorporation assays in response to titrated
doses of cytokine (Fig. 2 B). This revealed a large right shift
in dose–response for the 32D[mAR] clones. However,
even at maximal G-CSF concentrations, 32D[mAR] clones
failed to reach the same level of 3H-TdR incorporation as
those expressing the wild-type receptor. These data estab-
lish that the P206H mutation causes hyporesponsiveness to
G-CSF in myeloid cells.
The P206H Mutation Abrogates G-CSF–mediated Prolifera-
tion and Survival, but not Differentiation, in Myeloid 32D
Cells. We next sought to determine the effect of the
P206H mutation on long-term proliferation, survival, and
neutrophilic differentiation responses to G-CSF. There-
fore, 32D cell clones were switched from IL-3– to G-CSF–
containing medium after extensive washing to remove re-
sidual IL-3. Without IL-3 or G-CSF, all transfectants died
within 1–2 d and showed no signs of neutrophilic differen-
tiation. Parental 32D.cl8.6 cells and cells transfected with
empty LNCX vector also died within 1–2 d in G-CSF–
containing medium. However, the 32D[WT] cells prolif-
erated in response to G-CSF for 6–7 d (Fig. 3 A). After
6–8 d, these cells developed into terminally differentiated
neutrophils, showing an enlarged cytoplasm/nucleus ratio,
lobulated nuclei, and neutrophilic cytoplasm (Fig. 3 B,
middle). In contrast, 32D[mAR] cells showed an almost
complete block in G-CSF–mediated proliferation and re-
duced survival (Fig. 3 A). Since the bulk of the 32D[mAR]
cells fail to survive past 6 d, it is difficult to accurately quan-
titate the effect of the P206H mutation on differentiation.
However, most 32D[mAR] cells surviving until day 7
showed clear signs of neutrophilic differentiation (Fig. 3 B,
right). This suggests that differentiation signals per se are
not severely affected by the receptor mutation.
Altered Signaling from the P206H Mutant G-CSF-R in My-
eloid Cells. To further investigate the selective abrogation
of G-CSF–mediated proliferation and survival signals by
the mutant receptor, we analyzed STAT activation, since
STAT3 and STAT5 have been strongly implicated in con-
trol of G-CSF–mediated differentiation and proliferation/
survival, respectively (23, 24). In addition, STAT activation
Figure 2. Expression of wild-type and P206H mutant G-CSF-Rs in
myeloid 32D cells, and characterization of their G-CSF responsiveness.
(A) Flow cytometric analysis of G-CSF-R expression on parental
32D.cl8.6 cells (32D) and 32D.cl8.6 cells expressing either wild-type
(32D[WT]) or P206H mutant (32D[mAR]) receptors. Cells were either
stained with biotinylated mouse anti–human G-CSF-R antibodies fol-
lowed by PE-conjugated streptavidin, biotinylated antistreptavidin, and
finally PE-conjugated streptavidin (open), or without the anti–G-CSF-R
step (shaded). (B) G-CSF dose–response of representative 32D[WT] and
32D[mAR] clones in a 24-h thymidine-incorporation assay, as indicated.
Data are expressed relative to the response to IL-3.  o
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represents a sensitive measure of receptor activation. This
analysis revealed that, compared with 32D[WT] control
cells, 32D[mAR] cells showed reduced activation of all
STAT proteins and a delay in the time of peak activation
from 10–15 min to 30 min, indicating defective receptor
activation (Fig. 4 A). Interestingly, however, the quantita-
tive effect on STAT1 and STAT5 activation was signifi-
cantly greater than on STAT3. Examination of the dose–
response of STAT activation showed a decrease in sensitivity
for STAT activation from the mutant receptor, with again
a larger effect on STATs 1 and 5 than on STAT3 (Fig. 4
B). We also examined activation of the Ras–mitogen-acti-
vated protein kinase (MAPK) pathway by examining extra-
cellular signal regulatory kinase (Erk) phosphorylation. This
was also both delayed and reduced in cells expressing mu-
tant receptors (data not shown), suggesting that different
pathways are altered to varying degrees by the receptor
mutation.
P206H Mutant Receptors Show Reduced Ligand Binding.
Given the drastic effects of the P206H mutation on both
signaling pathways and biological responses from the
G-CSF-R, as well as its proximity to the ligand binding
sites on the receptor (41–43), we investigated whether al-
tered ligand binding could explain our results. Scatchard
analyses on 32D[WT] and 32D[mAR] clones showed that
ligand binding affinity (Kd) was unaffected by the mutation
(Table I). However, it was apparent in the analyses that the
32D[mAR] clones showed decreased total ligand binding.
To quantitate this more precisely, we analyzed a pair of
clones almost exactly matched for receptor levels as deter-
mined by FACS® with anti–G-CSF-R antiserum. This re-
vealed a clear reduction in total binding sites on mAR re-
ceptors, to approximately half that on wild-type G-CSF-Rs
(Table I). We also performed similar analyses on Ba/F3
clones expressing WT and mAR receptors, and obtained
similar results (Table I). As a further independent test of the
relative ligand binding properties of the wild-type and mu-
tant G-CSF-Rs, we compared binding of biotinylated
G-CSF to those 32D clones that expressed nearly identical
levels of WT or mAR receptors by anti–G-CSF-R bind-
ing. Again there was a clear reduction in the quantitative
binding of ligand to mAR receptors (Fig. 5).
Wild-type Receptors Stimulated with Nonsaturating G-CSF
Concentrations Mimic the Effect of the P206H Mutation. The
data above suggested that mutant mAR receptors have an
altered stoichiometry of ligand–receptor complex forma-
tion, which may be responsible for their altered signaling
properties. To directly test this hypothesis, we stimulated
32D[WT] cells with saturating and nonsaturating G-CSF
levels, which should favor formation of different receptor
complexes (see Discussion). This analysis revealed that the
use of nonsaturating G-CSF concentrations (0.3 ng/ml,
which is .30 times lower than the receptor Kd [44]) elicits
responses that largely mimic the P206H mutant phenotype.
At this concentration, cells showed decreased proliferation
and survival (Fig. 6 A), although again some differentiated
cells were observed (data not shown), while STAT activa-
tion, particularly of STATs 1 and 5, was decreased and de-
layed (Fig. 6 B).
Mutant Receptors Inhibit Signaling from Wild-type Receptors.
Since the patient harbors a heterozygous mutation in the
GCSFR gene, we sought to coexpress both wild-type and
mutant receptors in the same cells in order to more accu-
rately recapitulate the clinical situation. To achieve this, we
Figure 3. Effect of the P206H
mutation on G-CSF–mediated
growth and differentiation. (A)
Cell proliferation of 32D[WT]
and 32D[mAR] cells on 100
ng/ml G-CSF, as indicated.
Data represent the mean growth
of three clones. (B) Morphologi-
cal features of representative
32D[WT] cells in the presence
of IL-3, and 32D[WT] or
32D[mAR] cells after 7 d expo-
sure to G-CSF, as indicated. For
the 32D[mAR] clone, the posi-
tions of an apoptotic cell and a
differentiated cell are indicated
with a light and bold arrow, re-
spectively.
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recloned both WT and mAR GCSFR cDNAs separately
into the retroviral expression vector pBabe, which harbors
a puromycin-resistance gene. Infectious retrovirus was sub-
sequently produced using the Phoenix A amphotropic
packaging line, and used to infect 32D[WTNeo] cells, which
express the wild-type G-CSF-R from the neomycin-resis-
tance encoding pLNCX vector. Subsequent bulk selection
on puromycin yielded cells expressing just wild-type recep-
tor (32D[WTNeo/WTPuro] cells) or coexpressing wild-type
and mutant receptors (32D[WTNeo/mARPuro] cells).
FACS® analysis of these bulk cultures revealed an increase
in G-CSF-R expression due to the introduction of the
pBabe retrovirus (Fig. 7 A). Northern blot analysis con-
firmed the presence of GCSFR transcripts from both
pLNCX and pBabe expression vectors (data not shown).
When these cultures were switched from IL-3 to G-CSF,
the 32D[WTNeo/WTPuro] cells showed substantially more
proliferation than 32D[WTNeo/mARPuro] cells, especially at
low G-CSF concentrations (Fig. 7 B). Finally, analysis of
G-CSF–induced STAT5 activation in these cells showed
that the presence of the mutant receptor also suppressed the
wild-type receptor signal in this regard, producing an al-
tered dose–response of activation (Fig. 7 C).
Discussion
SCN is a heterogeneous disorder defined by a severe re-
duction in blood neutrophil count—the result of a matura-
tion arrest at the promyelocyte/myeloid stage defect in the
bone marrow (1–3). The molecular mechanisms leading to
SCN remain largely unknown. However, G-CSF treat-
ment can restore granulopoiesis in the majority of SCN pa-
tients, which suggests that defects in G-CSF signal trans-
duction might be important in the etiology of the disease.
Indeed, in a subset of these G-CSF–responsive SCN pa-
tients, mutations have been identified in the cytoplasmic
domain of the G-CSF-R that generate truncated receptors
defective in G-CSF maturation signaling (25–28, 34). Al-
though these mutations correlate well with leukemic pro-
gression from SCN, their exact contribution to neutrope-
nia is still controversial. The mutation described in this
report represents a novel G-CSF-R mutation affecting the
extracellular domain of the receptor in an SCN patient
who was hyporesponsive to G-CSF treatment. Introduc-
tion of this P206H mutant receptor into myeloid cells re-
produces the hyporesponsiveness to G-CSF, severely
affecting proliferation and survival, although not differenti-
ation, responses to G-CSF. These data further highlight the
Figure 4. Effect of P206H mutation on G-CSF–mediated STAT acti-
vation. (A) Kinetics of STAT activation in 32D.cl8.6 cells expressing
wild-type G-CSF-R (WT) or P206H mutant (mAR) receptor. Serum-
and growth factor–deprived cells were incubated at 378C without factor
or with 100 ng/ml G-CSF for the times indicated. Nuclear extracts were
prepared and incubated with 32P-labeled double-stranded m67 or b-cas
oligonucleotides, as indicated. The relative position and identity of STAT
complexes are shown: S1, STAT1; S3, STAT3; S5, STAT5. (B) G-CSF
dose–response of STAT activation in 32D[WT] and 32D[mAR] cells as
described in A, except after stimulation for 15 min with the indicated
concentrations of G-CSF.
Table I. Scatchard Analysis of Clones Expressing Wild-type (WT) 
and P206H Mutant (mAR) G-CSF-Rs
Cell line Receptor type
Kd
(mean, n 5 3)
Sites/cell
(matched)
pM
32D WT 6.5 3 102 460
mAR 4.4 3 102 230
Ba/F3 WT 8.0 3 102 510
mAR 5.2 3 102 200
Figure 5. Binding of G-CSF to wild-type and P206H mutant recep-
tors. FACS® analysis of 32D parental (light gray shaded, dotted line),
32D[WT] (dark gray shaded, no line), or 32D[mAR] (open, bold line)
clones with either a–G-CSF-R antiserum or biotinylated G-CSF, as in-
dicated.
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importance of GCSFR mutations in the pathophysiology
of SCN, and also for the first time implicate such mutations
in hyporesponsiveness to G-CSF therapy. In addition, the
mutation also severely, but selectively, abrogates signaling
from the G-CSF-R, apparently due to altered ligand–
receptor complex formation, which contributes to our un-
derstanding of cytokine receptor function.
How does the P206H mutation lead to the observed de-
fects in receptor function? It is clear that the mutation af-
fects ligand–receptor stoichiometry, such that the number
of ligand binding sites per receptor is reduced, suggesting
that the mutation alters the molecular architecture of the
receptor complex. Using purified G-CSF-R, Fukunaga et al.
have shown that high-affinity G-CSF-Rs consist of oligo-
mers (44). From studies with isolated recombinant do-
mains, it appears that G-CSF can bind to the isolated BN
and BC subdomains of the G-CSF-R CRH region in a 1:1
stoichiometry (42, 43). However, unlike other receptors,
the G-CSF-R requires its Ig domain in addition to its
CRH domain for high-affinity binding and oligomeriza-
tion (45, 46). From these and other studies, Hiraoka et al.
have proposed a model for the interaction of G-CSF with
its receptor—at low ligand concentrations, an asymmetric
2:1 receptor–ligand complex is formed, whereas at high
G-CSF concentrations, this converts to a 4:4 receptor–
ligand tetramer (45). In contrast, Horan et al. have impli-
cated a conversion instead from a 2:1 to a 2:2 receptor–
Figure 6. Analysis of signaling from the wild-type G-CSF-R at saturat-
ing and nonsaturating G-CSF concentrations. (A) Growth of 32D[WT]
cells at either 100 or 0.3 ng/ml G-CSF, as indicated. (B) STAT activation
in 32D[WT] cells at either 100 or 0.3 ng/ml G-CSF, as indicated, per-
formed as described in the legend to Fig. 4 A.
Figure 7. Analysis of 32D cells coexpressing wild-type and mutant recep-
tors. (A) FACS® analysis of 32D[WTNeo], 32D[WTNeo/WTPuro], and
32D[WTNeo/mARPuro] cells with a–G-CSF-R antiserum, as described in the
legend to Fig. 2 A. In the bottom panels, the dotted line represents the
G-CSF-R expression level of the original 32D[WTNeo] clone. (B) Growth of
32D[WTNeo/WTPuro] cells (filled circles) or 32D[WTNeo/mARPuro] cells (filled
triangles) at G-CSF concentrations of either 100 ng/ml (solid line) or 1 ng/ml
(dashed line). The growth curve of the original 32D[WTNeo] clone at 100 ng/
ml G-CSF is included for comparison (open squares, dotted line). (C) G-CSF–
induced STAT5 activation in 32D[WTNeo/WTPuro] cells (WT) or
32D[WTNeo/mARPuro] cells (mAR), as described in the legend to Fig. 4 B.
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ligand complex depending on G-CSF concentration (47,
48). Regardless of the exact composition, this ligand con-
centration–dependent transition to a higher order complex
involving the Ig domain contrasts with other hematopoi-
etin receptors, such as growth hormone receptor, which
only requires its CRH region to form a simple, symmetri-
cal 2:1 receptor–ligand complex (13, 49). In addition, we
have recently shown that the ligand sensitivity for STAT3
activation is z1 log higher than for activation of STATs 1
and 5 from the wild-type G-CSF-R (22). This suggests that
different intracellular signaling complexes are also formed
depending on ligand concentration: at low concentrations,
one that can activate STAT3, and at high concentrations,
one that can activate all three STATs.
The P206H mutation we have identified lies in a short
connecting loop or hinge between the BN and BC subdo-
mains of the CRH region (39). From the structures of the
CRH region from the closely related gp130 receptor com-
ponent (50) and the isolated BC domain of the G-CSF-R
(51), we can expect this mutation to impact on the b-sheet
angles as well as on the relative orientation of the BN and
BC domains. In addition, we have shown that this muta-
tion leads to a reduction in ligand binding sites, and pro-
duces a drastic effect on signaling and biological responses.
In light of this data and the studies detailed above, we
would propose the following model for the signaling com-
plexes formed with wild-type and P206H mutant receptors
at different ligand concentrations (Fig. 8). At low ligand
concentration, wild-type receptors form a 2:1 complex that
can activate a subset of signaling pathways, including
STAT3 (weak signal). At high ligand concentration, there
is a shift to a higher order complex (2:2 or 4:4), which can
activate all pathways, including STATs 1 and 5 (strong sig-
nal). In contrast, the mAR receptor is able to form the
asymmetric 2:1 complex normally, but the P206H muta-
tion perturbs the receptor in a manner that blocks higher
order binding. This would explain the 50% reduction in
binding sites per mutant receptor in spite of an unaltered
receptor Kd, as well as the ability of the mutant to elicit
only weak intracellular signals (such as STAT3), i.e., equiv-
alent to the complex formed when the wild-type receptor
is stimulated at low G-CSF concentration, with similar bio-
logical outcomes. Consistent with this model, a G-CSF-R
mutant in which the Ig domain was deleted, which could
presumably form a 2:1 but not a higher order complex, also
retained a very weak signal transducing ability (41).
Recently, the X-ray structure of the EpoR extracellular
domain has been solved (52, 53). These studies have re-
vealed that the EpoR is present as a dimer in the absence of
ligand, with ligand binding inducing a conformational
change of the dimer necessary for signal transduction. Im-
portantly, this is accompanied by an alteration in the inter-
domain angle between the BN and BC subdomains. Our
data are consistent with this model, and further suggest that
there may indeed be a two-step conformational change in
the G-CSF-R as more ligand binds to the receptor com-
plex, the latter of which is impaired by the P206H muta-
tion, which lies in a prime position to perturb the interdo-
main angle.
Our suggestion of a ligand concentration–dependent
switch in complex formation of the wild-type receptor
may also have important consequences for understanding
the control of basal versus “stress” granulopoiesis from the
G-CSF-R. Recent data have implicated STAT3 activation
in the control of differentiation from the G-CSF-R (22,
23), whereas STAT5 seems important in the control of
G-CSF–mediated proliferation and survival (24). Thus, we
would envisage a switch from a differentiation function
(STAT3) at basal G-CSF levels, to a proliferative/survival
function (STAT5, and other pathways?) when G-CSF lev-
els are elevated to facilitate a rapid expansion of the granu-
locytic compartment, such as in response to infection.
The identification of a mutation in the extracellular do-
main of the G-CSF-R in an SCN patient unresponsive to
Figure 8. Model for receptor–
ligand complexes formed with
WT and mAR (P206H) mutant
G-CSF-Rs.
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normal G-CSF treatment has important ramifications. First,
PCR screening for GCSFR mutations in SCN is currently
confined to the cytoplasmic region of the receptor. Our
data suggest the need for a more complete analysis, particu-
larly in “nonresponders” to G-CSF. Second, as our un-
derstanding of the biological consequences of different
G-CSF-R or other mutations in SCN increases, it would
seem appropriate in the future to prescribe different treat-
ments to different categories of SCN patients. In this re-
gard, it will be of interest to determine whether the use of
prednisone in combination with G-CSF may be of benefit
for other patients hyporesponsive to standard G-CSF therapy.
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